TNSN06370A1 - PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - Google Patents

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

Info

Publication number
TNSN06370A1
TNSN06370A1 TNP2006000370A TNSN06370A TNSN06370A1 TN SN06370 A1 TNSN06370 A1 TN SN06370A1 TN P2006000370 A TNP2006000370 A TN P2006000370A TN SN06370 A TNSN06370 A TN SN06370A TN SN06370 A1 TNSN06370 A1 TN SN06370A1
Authority
TN
Tunisia
Prior art keywords
dans
des
anormale
traitement
une
Prior art date
Application number
TNP2006000370A
Other languages
French (fr)
Inventor
Lu
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06370(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06370A1 publication Critical patent/TNSN06370A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (I) : Dans laquelle R1 à R4 répondent aux définitions figurant dans le présent mémoire. Ces dérivés de pyrimidine nouveaux sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
TNP2006000370A 2004-05-14 2006-11-13 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH TNSN06370A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
TNSN06370A1 true TNSN06370A1 (en) 2008-02-22

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000370A TNSN06370A1 (en) 2004-05-14 2006-11-13 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN1953974A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
KR101060051B1 (en) * 2005-12-21 2011-08-29 화이자 프로덕츠 인크. Pyrimidine Derivatives to Treat Abnormal Cell Growth
KR101132880B1 (en) * 2007-04-18 2012-06-28 화이자 프로덕츠 인크. Sulfonyl amide derivatives for the treatment of abnormal cell growth
WO2009012421A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
ES2645689T3 (en) * 2008-05-21 2017-12-07 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (en) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5 inhibitor
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 Isoindolinone-containing ERK inhibitor and preparation method and application thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AP2385A (en) * 2002-12-20 2012-03-23 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.

Also Published As

Publication number Publication date
CN102127058A (en) 2011-07-20
CR8749A (en) 2006-12-05
AU2009238255A1 (en) 2009-12-03
PE20060240A1 (en) 2006-04-01
ZA200608394B (en) 2008-05-28
NO20064576L (en) 2006-11-07
UY28894A1 (en) 2005-12-30
GT200500113A (en) 2006-01-10
PA8632601A1 (en) 2006-06-02
NL1029045A1 (en) 2005-11-15
AU2005243397A1 (en) 2005-11-24
AP2241A (en) 2011-06-01
TW200539871A (en) 2005-12-16
NL1031845C2 (en) 2006-11-23
JP4099212B2 (en) 2008-06-11
MA28583B1 (en) 2007-05-02
MXPA06011890A (en) 2006-12-14
NZ550448A (en) 2010-11-26
JP2007537234A (en) 2007-12-20
EP1751143A1 (en) 2007-02-14
BRPI0511138A (en) 2007-11-27
CA2566707A1 (en) 2005-11-24
KR20070012477A (en) 2007-01-25
WO2005111023A1 (en) 2005-11-24
KR100886990B1 (en) 2009-03-04
TWI303635B (en) 2008-12-01
AR049097A1 (en) 2006-06-28
EA200601796A1 (en) 2007-04-27
GEP20104875B (en) 2010-01-11
NL1029045C2 (en) 2006-06-02
ECSP066997A (en) 2007-02-28
NL1031845A1 (en) 2006-07-31
IL178828A0 (en) 2007-03-08
AP2006003790A0 (en) 2006-10-31
CN1953974A (en) 2007-04-25

Similar Documents

Publication Publication Date Title
TNSN06370A1 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TN2009000428A1 (en) SULFONYLAMIDE DERIVATIVES FOR TREATING ABNORMAL CELL GROWTH
MA30075B1 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
MA31466B1 (en) BENZIMIDAZOLE DERIVATIVES
MA54327B1 (en) Kras g12c inhibitors
TNSN06358A1 (en) SUBSTITUTED METHYL-ARYL-OR-HETEROARYL-AMIDES
MA30526B1 (en) PROLYL HYDROXYLASE INHIBITORS
TNSN02012A1 (en) NOVEL PYRIMIDINE DERIVATIVES OF MMP INHIBITORS, AND COMPOSITIONS CONTAINING THEM
MA31655B1 (en) CYCLOPENTA [D] HYDROXYLATED AND METHOXYLATED PYRIMIDINES AS INHIBITORS OF AKT PROTEIN KINASE.
TNSN05249A1 (en) BENZOPYRANS USEFUL FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
TNSN06360A1 (en) 4-phenylamino-quinazolin-6-YL-AMIDES
TNSN07476A1 (en) N- (PYRIDINE -2- YL) - SULFONAMIDE DERIVATIVES
MA27389A1 (en) NEW BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS.
MA30784B1 (en) PHENYL DERIVATIVES AND THE USE THEREOF AS IMMUNOMODULATORS.
TNSN06347A1 (en) MORPHOLINE DERIVATIVES
MA31419B1 (en) PYRIDINE DERIVATIVES
MA27561A1 (en) AMINOINDAZOLES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
MA30428B1 (en) DERIVATIVES OF DIHYDROPYRAZOLOPYRIMIDINONES
TNSN08196A1 (en) PYRAZINE DERIVATIVES
TNSN08306A1 (en) SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES
MA29377B1 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
ATE368031T1 (en) NEW GAMMA SECRETASE INHIBITORS
TNSN06359A1 (en) ARYL-OR HETEROARYL-AMIDES SUBSTITUTED IN ORTHO POSITION
MA51204B1 (en) Pharmaceutical forms comprising a plasma kallikrein inhibitor
MA34361B1 (en) TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES